LETTERS TO THE EDITOR Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts The two major types of transcripts1 of the BCR-ABL1 oncoprotein are b2a2 (e13a2) and b3a2 (e14a2). These transcripts are observed in over 95% of patients with chronic myeloid leukemia in chronic phase (CML-CP) at the time of initial presentation. Very rarely (

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts. - PDF Download Free
271KB Sizes 0 Downloads 0 Views
Download PDF

Recommend Documents

Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Treatment of chronic phase chronic myeloid leukemia with imatinib.
Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia.
Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia.
Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Follow Us

Copyright © 2024 D.DOCKSCI.COM. All rights reserved. | Design by w3layouts